David Weitz and John Boyce are among the co-founders of GnuBio, a Harvard University spinout that plans to develop fast and inexpensive microdroplet-based DNA sequencing technology (see article, this issue).
Weitz is a professor of physics and applied physics at Harvard. He is also a co-founder of microdroplet firm RainDance Technologies. Previously, he was a professor of physics at the University of Pennsylvania, and before that, a physicist at Exxon Research and Engineering. He holds a PhD in physics from Harvard.
Boyce is the co-founder of consulting firm Delphi Bio and co-head of business development, sales, and marketing at Affomix. Prior to that, he was head of business development and scientific collaborations at Helicos BioSciences, and before that, he was senior director of commercial development at Parallele Biosciences, now part of Affymetrix, and senior director of sales and marketing at Sequenom.